AICAR

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), known clinically as acadesine, is a nucleoside analog that has attracted sustained scientific interest for its ability to activate AMP-activated protein kinase (AMPK), one of the most important energy-sensing enzymes in mammalian cells. With a molecular weight of 258.23 Da and the formula C9H14N4O5, AICAR sits at an unusual intersection of metabolism research, cardiology, oncology, and sports science.

Researchers first investigated AICAR in the 1980s and 1990s primarily as a cardioprotective agent during cardiac surgery. The logic was straightforward: activating AMPK during periods of ischemia, when heart tissue is starved of oxygen, might help cells survive metabolic stress. A series of clinical trials explored acadesine in coronary artery bypass graft surgery, though those trials produced mixed results and the compound was never approved in the United States.

Interest in AICAR expanded significantly once researchers recognized how central AMPK is to metabolic diseases. Because AMPK activation increases glucose uptake in muscle, suppresses fat synthesis, and promotes mitochondrial biogenesis, AICAR became one of the most widely used research tools for studying type 2 diabetes, obesity, and exercise physiology. In animal studies, AICAR treatment produced metabolic improvements that resembled the effects of aerobic exercise, a finding that drew widespread scientific and public attention.

What makes AICAR particularly interesting to researchers is also a source of caution. A 2021 systematic review published in Cells (PMID 34064363) carefully documented that AICAR has important biological effects that are entirely independent of AMPK. These off-target effects, involving purine metabolism, inflammatory pathways, and folate-dependent nucleotide synthesis, complicate interpretation of many older studies that attributed all AICAR effects to AMPK activation alone.

More recent work has moved in targeted therapeutic directions. Studies published between 2024 and 2025 have examined AICAR's potential to protect the heart from doxorubicin-induced toxicity, reverse diabetic peripheral neuropathy, and modulate the inflammatory environment in osteoarthritis joints. These research threads reflect a compound that, despite decades of investigation, continues to reveal new biology and therapeutic potential.

AICAR's primary mechanism depends on intracellular conversion. Once taken up by cells via adenosine transporters, AICAR is phosphorylated by adenosine kinase to form ZMP (5-aminoimidazole-4-carboxamide ribonucleotide monophosphate). ZMP structurally resembles AMP and binds to the gamma subunit of AMP-activated protein kinase (AMPK), mimicking the low-energy signal that activates this enzyme under conditions of energy stress, such as exercise, fasting, or hypoxia.

Activated AMPK phosphorylates a wide range of downstream targets. It stimulates glucose transporter type 4 (GLUT4) translocation to the cell surface, increasing glucose uptake in skeletal muscle independent of insulin signaling. AMPK also phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and thereby relieving inhibition of carnitine palmitoyltransferase 1, which promotes fatty acid oxidation. Simultaneously, AMPK suppresses mTORC1 activity, slowing anabolic processes and protein synthesis when cellular energy is insufficient.

Beyond these canonical effects, AICAR influences mitochondrial dynamics. Research has shown it promotes mitophagy, the selective clearance of damaged mitochondria, through pathways involving PINK1 and Parkin. A 2024 study in the International Journal of Molecular Sciences (PMID 39795939) demonstrated that AICAR prevented and reversed diabetic polyneuropathy in animal models by restoring mitophagy in peripheral nerve tissue, suggesting mitochondrial quality control as a distinct therapeutic mechanism.

A 2021 systematic review in Cells (PMID 34064363) confirmed that AICAR also has meaningful AMPK-independent effects. ZMP is an intermediate in the purine biosynthesis pathway and can inhibit adenylosuccinate lyase and AICAR transformylase, enzymes involved in de novo purine synthesis. This results in accumulation of upstream purine intermediates and can influence adenosine release and downstream adenosine receptor signaling. Adenosine receptors, particularly A1 and A2A subtypes, mediate anti-inflammatory and cardioprotective effects that may occur in parallel with AMPK activation.

In the context of cardiac protection, AICAR appears to act through both AMPK-dependent preservation of energy homeostasis and AMPK-independent suppression of autophagy and oxidative stress pathways. A 2025 study in Cell and Molecular Life Sciences (PMID 41231272) reported that AICAR inhibited cardiomyocyte autophagy and promoted p62-dependent NRF2 expression, a pathway that enhances antioxidant defenses against doxorubicin toxicity.

Research on AICAR spans cardiac biology, metabolic disease, oncology, and rheumatology, with the most active recent work concentrated in cardioprotection and peripheral neuropathy.

In cardiology, a 2024 study published in the Journal of Molecular and Cellular Cardiology (PMID 38643934) investigated AICAR as a prophylactic treatment in a rat model of doxorubicin-induced heart failure. The study found that pre-treatment with AICAR preserved cardiac function and reduced markers of myocardial injury, suggesting a potential role in protecting cancer patients receiving cardiotoxic chemotherapy. This finding was extended by a 2025 study in Cell and Molecular Life Sciences (PMID 41231272), which found that AICAR inhibited cardiomyocyte autophagy and promoted NRF2-mediated antioxidant signaling through p62 accumulation, offering a mechanistic explanation for the earlier cardiac findings.

In metabolic disease and neuropathy, a 2024 study in the International Journal of Molecular Sciences (PMID 39795939) reported that AICAR both prevented and reversed diabetic polyneuropathy in animal models. The mechanism involved restoration of mitophagy in peripheral nerve tissue, with treated animals showing significant recovery of nerve conduction velocity and reduced oxidative damage. This represents one of the more clinically compelling recent findings, though the study was conducted entirely in rodents.

In rheumatology and joint disease, a 2025 study in the Journal of Nanobiotechnology (PMID 40203680) examined liposome-encapsulated AICAR delivered in a hydrogel format for osteoarthritis. The researchers found that this delivery system regulated macrophage metabolic reprogramming through activation of salt-inducible kinase 1 (SIK1) and downstream AMPK signaling, reducing joint inflammation in animal models. The use of encapsulated delivery addresses a known pharmacokinetic limitation of AICAR, which is cleared rapidly from circulation.

A critical contribution to the field came from a 2021 systematic review in Cells (PMID 34064363), which analyzed studies that used AICAR as an AMPK tool compound. The review found substantial evidence that many published AICAR effects involve AMPK-independent mechanisms, including interference with purine biosynthesis and adenosine receptor signaling. The authors concluded that results from AICAR studies must be interpreted cautiously and ideally confirmed with more selective AMPK activators.

From an oncology angle, a 2010 study in Cancer Biology and Therapy (PMID 20948309) identified AMPK as a therapeutic target in renal cell carcinoma, with AICAR demonstrating antiproliferative effects in cell lines. Human data on AICAR in cancer treatment remains limited to earlier cardiac surgery trials and small exploratory studies, none of which have produced regulatory approval.

In human clinical trials, acadesine (AICAR) was investigated primarily in cardiac surgery settings. Published trials used intravenous infusions ranging from approximately 0.1 mg/kg/min to 0.2 mg/kg/min administered perioperatively during coronary artery bypass graft surgery. These were controlled clinical settings with continuous monitoring. No completed human trial has established a safe or effective dose for metabolic, athletic performance, or neuroprotective applications in healthy or non-surgical populations. Figures circulating online for performance-enhancement purposes are unverified and have no basis in completed human research.

AICAR's safety profile is best understood in the context of its use in cardiac surgery patients, which represents the most controlled human data available. In those perioperative trials, the compound was generally tolerable at the doses studied, with the primary concerns being hemodynamic effects related to adenosine receptor activation, including transient reductions in heart rate and blood pressure. Hyperuricemia, an elevation of uric acid in the blood resulting from disruption of purine metabolism, was identified as a notable side effect and represents a mechanism-based concern given AICAR's role in the purine synthesis pathway, as discussed in a 2015 Advances in Nutrition review (PMID 26374178).

In animal studies, AICAR has generally shown tolerable acute toxicity at research doses, though prolonged or high-dose administration has produced effects consistent with excessive AMPK activation, including muscle fatigue and metabolic alterations. The AMPK-independent effects documented in the 2021 Cells systematic review (PMID 34064363) raise concerns about off-target consequences, particularly for cells with high rates of purine synthesis, such as rapidly dividing cells. Interference with de novo purine biosynthesis could theoretically affect immune function or tissue repair in ways that have not been fully characterized.

For individuals without cardiovascular disease or metabolic illness, no safety data from controlled human trials exists. This is an important gap. The compound's rapid clearance from circulation means that the pharmacokinetic profile for non-intravenous administration routes is not well characterized in humans.

Anti-doping agencies have banned AICAR for use in athletic competition. A 2022 study in Drug Testing and Analysis (PMID 36342242) reported that the ratio of AICAR to its downstream metabolite SAICAr can serve as an additional biomarker for detecting AICAR use in anti-doping testing, indicating active development of detection methods. This classification reflects regulatory concern about its potential misuse rather than any confirmed record of broad human safety.

AICAR is an active area of preclinical research with a history of human clinical investigation in cardiac surgery that never led to regulatory approval. The compound has not received FDA approval for any indication. Current research activity, as reflected in publications from 2024 and 2025, centers on cardioprotection against chemotherapy-induced toxicity, diabetic peripheral neuropathy, and inflammatory joint disease.

Novel delivery strategies, including liposome-encapsulated hydrogel formulations, are being developed to address AICAR's pharmacokinetic limitations, particularly its short half-life in circulation. This suggests that future clinical translation may depend on improved delivery technology rather than systemic administration.

A key gap in the current literature is the lack of well-powered human trials outside cardiac surgery. Nearly all recent mechanistic and therapeutic data comes from rodent models. The extent to which AICAR's preclinical benefits translate to human metabolic disease, neuropathy, or cancer remains an open and important question.